Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action

Manabu Nagao¹, Hideto Nakajima¹, Ryuji Toh², Ken-ichi Hirata¹ and Tatsuro Ishida¹

¹Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
²Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

High-density lipoprotein cholesterol (HDL-C) has been identified as a powerful independent negative predictor of cardiovascular disease. The beneficial effect of HDL is largely attributable to its key role in reverse cholesterol transport, whereby excess cholesterol in the peripheral tissues is transported to the liver, reducing the atherosclerotic burden. However, mounting evidence indicates that HDL also has pleiotropic properties, such as anti-inflammatory, anti-oxidative, and vasodilatory properties, which may contribute in reducing the incidence of heart failure. Actually, previous data from clinical and experimental studies have suggested that HDL exerts cardioprotective effects irrespective of the presence/absence of coronary artery disease. This review summarizes the currently available evidence regarding beneficial effects of HDL on the heart beyond its anti-atherogenic property. Understanding the mechanisms of cardiac protection by HDL will provide new insight into the underlying mechanism and therapeutic strategy for heart failure.

Key words: High-density lipoprotein, Cardioprotective effect, Heart failure, Fatty acid, Endothelial lipase, mTOR signal

Introduction

Heart failure (HF) is the terminal state of all heart diseases and is the leading cause of mortality worldwide. According to the American Heart Association, there are approximately 550,000 new patients with HF each year¹. Although considerable advances have been made in our understanding of HF, the incidence, prevalence, mortality, and financial burden of the disease continue to steadily increase in the aging population. Therefore, elucidating modifiable risk factors for HF will aid in identifying prevention strategies or developing novel therapeutic approaches.

Numerous studies have established an inverse relationship between high-density lipoprotein cholesterol (HDL-C) and risk for atherosclerotic cardiovascular disease in humans²-⁵; low HDL-C is considered to be one of the most important coronary risk factors⁶. This beneficial effect of HDL on the cardiovascular system is largely attributable to its key role in reverse cholesterol transport (RCT), whereby excessive cholesterol in the peripheral tissues is transported to the liver, reducing the atherosclerotic burden. However, a large amount of evidence has revealed that HDL has many anti-atherosclerotic properties represented by anti-inflammatory, anti-oxidative, anti-thrombotic, anti-apoptotic, and vasodilatory properties, and these vasoprotective effects seem to be independent of RCT activity⁷, ⁸. Hence, it may be reasonable to consider that such properties of circulating HDL do not only protect the coronary vessel wall against atherosclerosis but also exert direct beneficial effects on the myocardium, leading to reduction of the incidence of myocardial diseases, including HF.

It has been well known that cigarette smoking has a negative impact on RCT and reduces circulating HDL-C levels, which is involved in the progression of cardiovascular disease⁹, ¹⁰. Conversely, several studies have suggested that HDL exerts atherosclerosis-independent cardioprotective effects on the pathological status. Horio et al. investigated the influence of serum lipids on LV functions in patients with essential hypertension and found that low HDL-C level is an independent pre-
dor of LV mass and LV diastolic dysfunction\textsuperscript{11}). An independent association between low HDL-C level and subclinical LV systolic dysfunction has been observed in patients with not only stable angina but also normal coronary angiogram\textsuperscript{13}, and Ketola et al. suggested that HDL is superior to B-type natriuretic peptide as a marker of systolic cardiac dysfunction in an elderly general population\textsuperscript{13}. Moreover, NIPPON DATA\textsuperscript{90}, a large cohort study of cardiovascular disease in Japan, addressed the association between HDL-C levels and HF incidence; serum HDL-C levels tended to show an inverse association with HF mortality with borderline significance and a significant inverse association with all-cause mortality\textsuperscript{14}. In line with this observation, Vredevoe et al. reported that HDL-C is a predictor of mortality in patients with idiopathic HF\textsuperscript{15}. Taken together, HDL exerts direct cardioprotective effects independent of the atheroprotective property, which possibly influences LV function and HF incidence. In the present review, we summarize currently available evidence regarding direct beneficial effects of HDL on the heart beyond the anti-atherogenic property and discuss underlying mechanisms that have been implicated.

1. HDL Provides Fatty Acids as Energy Substrates for the Myocardium

Vast amounts of energy are required for fueling the continuous pumping action of the heart. Under normal circumstances, nearly 70% of the energy substrate used for myocardial contraction is derived from fatty acid (FA) oxidation and the remainder comes from glucose, lactate, and ketone body oxidation\textsuperscript{16}. Thus, FAs are considered to be the major energy source for the myocardium, which are delivered to cardiomyocytes in three ways: 1) FAs are produced in the local capillary bed by hydrolysis of triglycerides (TGs) contained in circulating TG-rich lipoproteins (TRL), such as chylomicrons and very low-density lipoproteins (VLDL), via actions of lipoprotein lipase (LPL). 2) FAs are produced by hydrolysis of intracellular TG storages, and 3) FAs are derived from circulating free FAs, referred to as non-esterified FA (NEFA), complexed with serum albumin\textsuperscript{17}. Moreover, phospholipids might be one of the resources of FAs, whereas metabolic regulation in the heart remains to be fully elucidated. In particular, LPL-mediated lipolysis of chylomicrons and VLDL significantly contributes to cardiac energy supply\textsuperscript{18, 19}; therefore, LPL plays a central role in energy homeostasis in the heart\textsuperscript{17}. LPL is synthesized in cardiomyocytes and then migrates to the luminal surface of vascular endothelial cells where hydrolysis of TRL takes place\textsuperscript{20}. In contrast to esterified FAs derived from TRL, NEFA availability is limited because of its low solubility and high toxicity. Myocardium uptakes NEFA as an energy source by passive diffusion and several transporters, such as FA-binding protein, FA translocase (FAT/CD36), and FA transport protein\textsuperscript{16}. Hauton et al. investigated myocardial lipid substrate preference by comparing utilization of NEFA, VLDL-TGs, and CM-TGs in rat-isolated perfused hearts and concluded that myocardial utilization of NEFA and CM-TGs is higher than that of VLDL-TGs\textsuperscript{21}. Besides LPL-mediated lipolysis, there is an alternative mechanism by which TRL is assimilated into the heart. The VLDL receptor is a member of the LDL receptor gene family, which has high expression in the heart, and is associated with the uptake of apolipoprotein E-containing lipoproteins\textsuperscript{22, 23}. Although cardiomyocytes also express scavenger receptor class B type I (SR-BI), a receptor related to the uptake of cholesterol from HDL\textsuperscript{24, 25}, it remains unknown whether HDL particles are incorporated into the heart via SR-BI.

Cardiomyocytes possess endothelial lipase (EL), which is another member of the TG lipase family. Although basal expression of EL in cardiomyocytes is very low, its expression level is upregulated under pathological conditions, including inflammation, mechanical, and oxidative stress\textsuperscript{26}. EL is considered to bind to cell surface proteoglycans where it can directly interact with lipoproteins\textsuperscript{27-29}. EL primarily has phospholipase activity and relatively less TG lipase activity and exhibits preferential substrate specificity for phospholipids on HDL\textsuperscript{29}. Therefore, EL has the potential ability to release FAs from not only TGs contained in TRL but also phospholipids contained in HDL. However, relative contribution of EL-mediated HDL hydrolysis and TRL lipolysis in FA supply to the myocardium needs to be determined in the future.

A large amount of evidence suggests that cardiac energy metabolism is severely impaired in the failing heart\textsuperscript{26, 30}. Namely, the failing heart is commonly described as an energy-starved engine that has run out of fuel\textsuperscript{31}. During development of HF, the predominant myocardial energy substrate switches from FAs to glucose because glucose oxidation allows the heart to produce intracellular adenosine triphosphate (ATP) using less oxygen than that needed for FA oxidation\textsuperscript{31-33}. However, compromised cardiac energy metabolism may cause and worsen myocardial dysfunction. Total \(\beta\)-oxidation in the heart is increased by 40% in response to acute energy demand\textsuperscript{34} and increased glucose oxidation alone is reported to be insufficient to meet the cardiac energy requirement under stress conditions\textsuperscript{33, 35}. Augustus et al. reported that heart-specific LPL knockout (hLpL0) mice were susceptible to HF because of loss of LPL-mediated TG lipolysis in spite of increased glucose oxidation\textsuperscript{35}. They showed that hearts of hLpL0 mice that underwent abdominal aortic constriction were
unable to adapt acutely to pressure overload, thereby, all banded hLP.L0 mice died within 48 h, whereas all banded wild-type mice continued to thrive. Similarly, the lack of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1α), a regulator of numerous genes involved in FA import and oxidation, accelerates pressure overload-induced HF induced by transverse aortic constriction. These findings indicate that FAs are indispensable energy substrates even in the failing myocardium.

Kratky et al. observed that EL compensates for free FA uptake in LPL-deficient mouse adipose tissue, which indicates that EL provides an alternative pathway for FA uptake when the action of LPL is insufficient. Expression of EL in the cardiac tissues is increased in the early phase of pressure overload-induced HF, whereas expression of LPL is significantly decreased. Subsequently, EL deficiency worsens pressure overload-induced HF due to the attenuated energy production from FA oxidation, which suggests that EL-mediated FA supply from HDL is important for the myocardium in the setting of increased energy demand or insufficient LPL action. In addition, various FAs act as ligands for PPARα, which regulates mitochondrial FA oxidation-related genes. Ahmed et al. revealed that EL-mediated hydrolysis of HDL activates PPARα and subsequently upregulates the expression of acyl-CoA-oxidase, a well-established FA oxidation-related gene. In line with this finding, incubation of EL-overexpressing cardiomyocytes with HDL augmented the expression of FA oxidation-related genes carnitine palmitoyltransferase-1 and medium-chain acyl CoA dehydrogenase which was accompanied by an increase in intracellular ATP. From these findings, it is considered that EL-mediated FA supply from HDL not only increases energy substrates for the myocardium but also upregulates the expression of PPARα-mediated FA oxidation-related genes, thereby preserving FA utilization in the failing heart.

2. HDL Protects Cardiomyocytes Against Oxidative Stress

There is a well-established relationship between myocardial reactive oxygen species (ROS) levels and left ventricular contractile dysfunction, which results in HF. ROS is generated in the ischemic myocardium, particularly after reperfusion, leading to cell death. One of the most important properties of HDL is its ability to reduce oxidative stress caused by excessive ROS formation. There is evidence that HDL inhibits NAD(P)H oxidase-dependent ROS generation in vascular smooth muscle cells and isolated aortas. With regard to the myocardium, in an ex vivo model of ischemia-reperfusion (I/R) injury, Marchesi M et al. showed that synthetic HDL, recombinant apo A-I Milano complexed with 1-palmitoyl-2-oleoyl phosphatidylcholine, reduced cardiac muscle lipid hydroperoxide levels by 46% via its antioxidant potential, thereby attenuating post-ischemic LV dysfunction.

We recently reported that HDL treatment improved cardiomyocyte viability under oxidative stress through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway. mTOR belongs to the PI3K-related kinase family and critically regulates protein synthesis, cell survival, growth, and proliferation. In addition, several studies have identified mTOR as an important regulator of cardiac adaptation because its overexpression is protective in pressure-overloaded mouse hearts and its conditional knockout in murine heart causes cardiac dysfunction. We demonstrated that HDL activated downstream effectors of mTOR signaling, which played anti-apoptotic roles under oxidative stress, may contribute to cardioprotection.

3. HDL Exerts Anti-Inflammatory Effects in the Myocardium

HF is known as a disorder characterized in part by immune activation and inflammation. Niebauer et al. showed that plasma bacterial endotoxin (lipopolysaccharide, LPS) levels were increased in patients with HF and peripheral edema probably because venous congestion leads to altered gut permeability for endotoxin and translocation of the endotoxin into the systemic circulation. It has been postulated that low plasma cholesterol levels, a surrogate for the totality of lipoproteins, is related to impaired survival in patients with idiopathic HF. Similarly, Rauchhaus M et al. proposed that high plasma cholesterol levels in chronic HF are beneficial on the basis of the capacity of circulating cholesterol-rich lipoproteins to bind and inactivate endotoxin in proportion to their cholesterol content. It has been postulated that low plasma cholesterol levels, a surrogate for the totality of lipoproteins, is related to impaired survival in patients with idiopathic HF.
improves clinical outcome in rabbit gram-negative bacteremia models. Furthermore, targeted deletion of EL results in an increase in phospholipid and cholesterol content in HDL particles and thereby improves the survival rate of endotoxin shock in a mouse model of LPS-induced septic shock. These findings indicate that HDL can diminish detrimental effects of endotoxemia in vivo. Therefore, it is reasonable to assume that HDL protects against HF by attenuating the action of endotoxin in edematous patient with HF.

4. HDL Enhances Myocardial Perfusion Via Nitric Oxide-Mediated Vasodilatory Effects

There is evidence that HDL administration increases myocardial perfusion in vivo via nitric oxide (NO)-dependent mechanisms, suggesting that HDL acts as a coronary vasodilator. HDL mediates vasodilation via NO release. Nofer et al. reported that HDL stimulates NO release in human endothelial cells and induces vasodilation in isolated aortas via intracellular Ca²⁺ mobilization and Akt-mediated endothelial NO synthase (eNOS) phosphorylation. The vasoactive effect of HDL was mimicked by three lysophospholipids contained in HDL: sphingosine-1-phosphate (S1P), sphingosylphosphorylcholine (SPC), and lysosulfatide (LSF). Deficiency of the S1P3 receptor abolished vasodilatory effects of these lysophospholipids, which indicates that HDL functions as a carrier of bioactive lysophospholipids and induces NO-dependent vasodilation via S1P3 receptor. Conversely, Yuhanna et al. have shown that HDL activates eNOS via SR-BI through a process that requires apoA-I binding in endothelial cells, resulting in increased NO production. Afterward, it was identified that apoA-I interaction with SR-BI led to Src-mediated PI3K activation and then PI3K activated Akt kinase and mitogen-activated protein kinase pathways, both of which stimulate eNOS activity. Collectively, HDL activates eNOS in endothelial cells through dual signaling pathways involved in S1P receptors and SR-BI and causes NO-mediated vasodilation. In the heart, Levkau B et al. observed that administration of human HDL enhanced incorporation of the perfusion tracer ⁹⁹mTc-methoxyisobutylisonitrile into the murine heart in vivo by approximately 18%; this increase was completely abolished in mice deficient of endothelial NO synthase. Furthermore, the stimulatory effect of HDL on myocardial perfusion was preserved in S1P3-deficient mice, which implies that SR-BI-mediated, but not S1P3-mediated, eNOS activation in endothelial cells may be mainly related to the stimulatory effect of HDL on myocardial perfusion.

5. HDL Protects Cardiomyocytes by Activating Beneficial Signal Transducers in the Heart

Among HDL constituents that mediate diverse biological effects, S1P is one of the major lipid constituents of HDL; it has gained special attention because it may be responsible for many of the pleiotropic effects of HDL. The major source of S1P is hematopoietic cells (mainly erythrocytes, platelets, and leukocytes), whereas HDL serves as a major carrier of extracellular S1P in the plasma. Zhang et al. showed that HDL-associated S1P is the major determinant of the plasma S1P level and positively correlates with HDL-C and apo-

---

Fig. 1. HDL protected the cardiomyocytes from cell death and inflammatory damages
A) Rat neonatal cardiomyocytes were incubated with lipopolysaccharides (LPS) for 24 h. The mRNA level of TNF-α was evaluated by real-time PCR and calibrated with that of GAPDH. HDL attenuated LPS-induced expression of TNF-α in cardiomyocytes.
B) Rat neonatal cardiomyocytes were incubated in serum-depleted medium with or without HDL for 24 h, and cell viability was assessed by WST-1 assay. HDL protected the cardiomyocytes from serum starvation-induced cell death.
poprotein A-I (apo A-I) levels. S1P is a biologically active sphingolipid metabolite involved in numerous cell activities, including proliferation, differentiation, survival, cytoskeletal rearrangements, cell motility, immunity, and angiogenesis. These activities are mediated through binding of S1P to its cell surface G protein-coupled receptors, which comprise S1P1–5. Although the expression of S1P1 and S1P3 is limited to the immune and nervous system, S1P1, S1P2, and S1P3 are widely expressed in various cell types, including cardiomyocytes and endothelial cells. Tao et al. showed that treatment of isolated cardiomyocytes with HDL enhanced cell survival during hypoxia-reoxygenation. They found that HDL activates prosurvival signals, MEK1/2-ERK1/2 and PI3-kinase-Akt, via S1P1 and S1P3 receptors on cardiomyocytes, respectively. Conversely, Frias et al. demonstrated that HDL and its S1P component protected cardiomyocytes against doxorubicin-induced apoptosis through the S1P3-ERK1/2-STAT3-mediated pathway. Thelmeier et al. reported that HDL and S1P reduced the infarct size by inhibition of inflammatory neutrophil recruitment and cardiomyocyte apoptosis in a mouse model of myocardial I/R. Cardioprotective effects were completely absent in S1P3-deficient mice and was also canceled by pharmacological eNOS inhibition, indicating that HDL and S1P-mediated cardioprotection is dependent on S1P3-mediated pathway by NO-dependent mechanisms. They proposed that strategies designed to rapidly elevate HDL levels in general and their S1P content may improve prognosis of the myocardium against ischemia and reperfusion. In addition to S1P, the same group also reported that SPC, another HDL-associated sphingolipid, directly protects against myocardial I/R injury in vivo via the S1P3 receptor because of its diverse affinity to different receptor subsets.

Morel S et al. reported that HDL or S1P induced PKC-dependent phosphorylation of connexin43 (Cx43), a major myocardial gap junction protein responsible for rapid, synchronous transmission of cardiac action potential. They also observed that short-term treatment with HDL or S1P at the onset of reperfusion limited the infarct size induced by I/R insult, in part, by affecting Cx43 gap junction channels in cardiomyocytes. Conversely, the survivor activating factor enhancement (SAFE) pathway, a novel powerful prosurvival signaling pathway that is associated with the activation of the signal transducer and activator of transcription 3 (STAT3) and tumor necrosis factor-α (TNF-α), protects against I/R injuries. Frias MA et al. demonstrated that HDL protects against I/R injury by inhibition of mitochondrial mPTP opening, and this effect is mediated via activation of the SAFE pathway by HDL. This result suggests that HDL influences mitochondrial function in cardiomyocytes.

We found that HDL protects the cardiomyocytes from cell death (Fig. 1B). In addition, we have revealed that HDL treatment improves cardiomyocyte viability under oxidative stress and that the PI3K/mTOR signaling pathway mediates these effects. In this study, we demonstrated that HDL treatment increased phosphorylation of the ribosomal protein S6 kinase (S6K) and BCL2-associated agonist of cell death (BAD) under oxidative stress via PI3K/mTOR. S6K is known as a downstream effector kinase of mTOR signaling and is related to anti-apoptotic signaling through maintenance of BAD phosphorylation. Shend et al. reported that mTOR-complex 1 activity was essential for preserving cardiac function. Its deletion impaired cardiac function, leading to dilated cardiomyopathy and high mortality. Correspondingly, they showed that the mTOR-complex 2 was associated with preserving left ventricular contractile function of pressure-overloaded mouse hearts. Cardiac dysfunction due to transverse aortic constriction was more severe after ablation of rictor, a specific component of mTOR2. Thus, in terms of cardiac protection, HDL could be an important activator of mTOR signaling.

**Conclusion**

Increasing evidence in clinical and in experimental studies has underlined that HDL exerts many beneficial effects in addition to anti-atherogenic effects on the heart. Given that HF usually develops gradually on the basis of multifactorial disorders, including vascular, myocardial, and metabolic disorders, pleiotropic properties of HDL potentially help in maintaining normal cardiac function (Fig. 2). HDL may protect the myocardium by functioning as an energy fuel, NO-mediated vasodilator, and signaling molecule and by promoting anti-inflammatory and anti-oxidative effects. Although recent clinical trials using cholesteryl ester transfer protein (CETP) inhibitors or niacin did not verify the beneficial effects of HDL-C increasing therapy, the primary outcome in these studies largely seems to depend on the onset of atherosclerotic vascular diseases. Conversely, it has been shown that pharmacological modification of HDL phospholipids can improve HDL functions. A better understanding of the direct cardioprotective effects of HDL needs to be determined in humans for seeking novel therapeutic strategies of HF.

**Acknowledgments**

None
Fig. 2. Potential molecular mechanisms for HDL-mediated direct cardioprotective effects
HDL may protect the myocardium by fueling energy from its fatty acid (FA), stimulating nitric oxide (NO)-mediated vasodilation, activating intracellular signaling pathways, and promoting anti-inflammatory and anti-oxidative effects. TRL, TG-rich lipoprotein.

Notice of Grant Support
This work was supported by grants-in-aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science.

Conflicts of Interest
T.I. received lecture honoraria from MSD, Bayer Yakuhin, and Mochida. K.H. received research funds from MSD, Astellas, Abbott Vascular Japan, Otsuka, Mochida, Nihon Novartis, Boehringer Ingelheim, Japan Mediphysics, Bayer Yakuhin, Fuji-Film RI, Boston Scientific, Ono Yakuhin, Sanwa Kagaku, Dainippon Sumitomo, Bristol Meyers, Kowa, Dai-ichi Sankyo, Takeda and lecture honoraria from MSD, Mochida, Kowa, Takeda, Dai-ichi Sankyo, Nihon Boehringer Ingelheim, Termo. K.H. belongs to the endowed chair by Sysmex, St. Jude Medical, and Japan Medtronic. R.T. belongs to the endowed chair by Sysmex.

References
1) Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y, American Heart Association Council on E, Prevention, American Heart Association Council on Clinical C, American Heart Association Council on Cardiovascular N, American Heart Association Council on High Blood Pressure R, Quality of C, Outcomes Research Interdisciplinary Working G, Functional G and Translational Biology Interdisciplinary Working G. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008; 117: 2544-2565
2) Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalous-
dian S and Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986; 256: 2835-2838

3) Assmann G, Schulte H, von Eckardstein A and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124 Suppl: S11-S20

4) Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS and Tall AR. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004; 45: 948-953

5) Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W and Atherosclerosis Risk in Communities Study G. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001; 104: 1108-1113

6) Grundy SM, Cleeman JJ, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ, National Heart L, Blood I, American College of Cardiology F and American Heart A. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239

7) deGoma EM, deGoma RL and Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008; 51: 2199-2211

8) Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G and von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002; 161: 1-16

9) Craig WY, Palomaki GE and Haddow JE. Cigarette smoking and serum lipids and lipoprotein concentrations: an analysis of published data. BMJ. 1989; 298: 784-788

10) Shennan NM, Seed M and Wynn V. Variation in serum high-density lipoprotein cholesterol level evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008; 51: 2199-2211

11) Horio T, Miyazato J, Kamide K, Takiuchi S and Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003; 16: 938-944

12) Wang TD, Lee CM, Wu CC, Lee TM, Chen WJ, Chen MF, Liau CS, Sung FC and Lee YT. The effects of dyslipidaemia on left ventricular systolic function in patients with stable angina pectoris. Atherosclerosis. 1999; 146: 117-124

13) Kerola T, Nieminen T, Hartikainen S, Sulkava R, Vuolteenaho O and Kettunen R. High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population. Scand J Clin Lab Invest. 2009; 69: 865-872

14) Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ushima H and Group NDR. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis. 2006; 184: 143-150

15) Vredevoe DL, Woo MA, Doering LV, Brecht ML, Hamilton MA and Fonarow GC. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998; 82: 323-328

16) van der Vusse GJ, van Bilsen M and Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000; 45: 279-293

17) Augustus AS, Kako Y, Yagyu H and Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab. 2003; 284: E331-E339

18) Mardy K, Belke DD and Severson DL. Chylomicron metabolism by the isolated perfused mouse heart. Am J Physiol Endocrinol Metab. 2001; 281: E357-E364

19) Bharadwaj KG, Hiyama Y, Hu Y, Huggins LA, Ramakrishnan R, Abumrad NA, Shulman GI, Blaner WS and Goldberg IJ. Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem. 2010; 285: 37976-37986

20) Braun JE and Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J. 1992; 287 (Pt 2): 337-347

21) Hauot D, Bennett MJ and Evans RD. Utilisation of triacylglycerol and non-esterified fatty acid by the working rat heart: myocardial lipid substrate preference. Biochim Biophys Acta. 2001; 1533: 99-109

22) Niu YG and Evans RD. Very-low-density lipoprotein: complex particles in cardiac energy metabolism. J Lipids. 2011; 2011: 189876

23) Takahashi S, Kawarabayasi Y, Nakai T, Sakai J and Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A. 1992; 89: 9252-9256

24) Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH and Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996; 271: 518-520

25) Connelly MA, Klein SM, Azhar S, Abumrad NA and Williams DL. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J Biol Chem. 1999; 274: 41-47

26) Nakajima H, Ishida T, Satomi-Kobayashi S, Mori K, Hara T, Sasaki N, Yasuda T, Toh R, Tanaka H, Kawai H and Hirata K. Endothelial lipase modulates pressure overload-induced heart failure through alternative pathway for fatty acid uptake. Hypertension. 2013; 61: 1002-1007

27) Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M and Rader DJ. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999; 21: 424-428

28) Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintero M and American College of Cardiology F and American Heart A. Implications of recent guidelines. Circulation. 2004; 110: 227-239
endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J. 2010; 74: 2263-2270
30) Lopaschuk GD, Ushier JR, Folmes CD, Jaswal JS and Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010; 90: 207-258
31) Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007; 356: 1140-1151
32) Sack MN and Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int J Mol Med. 1998; 1: 17-24
33) Yamashita H, Bharadwaj KG, Ikeda S, Park TS and Goldberg IJ. Cardiac metabolic compensation to hypertension requires lipoprotein lipase. Am J Physiol Endocrinol Metab. 2008; 295: E705-E713
34) Goodwin GW, Taylor CS and Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998; 273: 29530-29539
35) Augustus AS, Buchanan J, Park TS, Hirata K, Noh HL, Sun J, Homma S, D’Armiento J, Abel ED and Goldberg IJ. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem. 2006; 281: 8716-8723
36) Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A and Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A. 2006; 103: 10086-10091
37) Kratky D, Zimmermann R, Wagner EM, Strauss JG, Jin W, Kostner GM, Haemmerle G, Rader DJ and Zechner R. Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. J Clin Invest. 2005; 115: 161-167
38) Willson TM, Brown PJ, Sternbach DD and Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000; 43: 527-550
39) Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Zucchelli P, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006; 98: 490-498
40) Ali Sheikh MS, Salma U, Zhang B, Chen J, Zhuang J and Ping Z. Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress. Oxid Med Cell Longev. 2016; 2016: 5893064
41) Ide T, Tsutsui H, Nomura T, Hanasaki T, Takahashi S, Ichikawa K, Utsumi H, Machida Y, Egashira K and Takeshita A. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000; 86: 152-157
42) Hara M, Toh R, Irino Y, Nakajima H, Oshita T, Tsuda S, Han T, Shinozuma M, Ishida T and Hirata KI. High-density lipoprotein protects cardiomyocytes from oxidative stress via the PI3K/mTOR signaling pathway. FEBS Open Bio. 2017; 7: 1402-1409
43) Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M and Nofer JR. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemotactic protein-1 production. Arterioscler Thromb Vasc Biol. 2008; 28: 1542-1548
44) Marchesi M, Booth EA, Rossoni G, Garcia RA, Hill KR, Sirtori CR, Bissiger CL and Lucchese BR. Apolipoprotein A-I-Milano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis. 2008; 197: 572-578
45) Nagao M, Toh R, Irino Y, Nakajima H, Oshita T, Tsuda S, Han T, Shinozuma M, Ishida T and Hirata KI. High-density lipoprotein protects cardiomyocytes from oxidative stress via the PI3K/mTOR signaling pathway. FEBS Open Bio. 2017; 7: 1402-1409
46) Sbarbassov DD, Ali SM and Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005; 17: 596-603
47) Song X, Kusakari Y, Xiao CY, Kinsella SD, Rosenberg MA, Scherrer-Crosbie M, Han T, Rosenzweig A and Matsui T. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am J Physiol Cell Physiol. 2010; 299: C1256-C1266
48) Scharer CH, Volpe M and Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res. 2014; 114: 549-564
49) Zhang D, Contu R, Laronico MV, Zhang J, Rizzi R, Catalucci D, Miyamoto S, Huang K, Ceci M, Gu Y, Dalton ND, Peterson KL, Guan KL, Brown JH, Chen J, Sonenberg N and Candorelli G. Mtorc1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest. 2010; 120: 2805-2816
50) Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L and Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiovasc Rep. 2007; 9: 236-241
51) Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ and Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999; 353: 1838-1842
52) Rauchhaus M, Coats AJ and Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356: 930-933
53) Fleget WA, Baumstark MW, Weinstock C, Berg A and Northhoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun. 1993; 61: 5140-5146
54) Ulevitch RJ, Johnston AR and Weinberg DB. New function for high density liproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 1979; 64: 1516-1524
55) Levine DM, Parker TS, Donnelly TM, Walsh A and Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993; 90: 12040-12044
56) Hubsch AP, Casas AT and Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med. 1995; 126: 548-558
57) Hara T, Ishida T, Kojima Y, Tanaka H, Yasuda T, Shinozuma M, Toh R and Hirata KI. Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo. J Lipid Res. 2011; 52: 57-67
58) Levkau B, Hermann S, Theilmeyer G, van der Giet M, Chun J, Schober O and Schafers M. High-density lipo-
protein stimulates myocardial perfusion in vivo. Circulation. 2004; 110: 3355-3359

59) Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J and Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004; 113: 569-581

60) Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH and Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001; 7: 853-857

61) Saddar S, Mineo C and Shaul PW. Signaling by the high-affinity HDL receptor scavenger receptor B type 1. Arterioscler Thromb Vasc Biol. 2010; 30: 144-150

62) Sattler K and Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009; 82: 201-211

63) Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S, Noda K, Okajima F and Saku K. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis. 2005; 178: 199-205

64) Keul P, Sattler K and Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007; 12: 301-306

65) Blaho VA and Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014; 55: 1596-1608

66) Means CK and Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res. 2009; 82: 193-200

67) Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS and Raffai R. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol. 2010; 298: H1022-H1028

68) Frias MA, Lang U, Gerber-Wicht C and James RW. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res. 2010; 85: 118-126

69) Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, Mersmann J, Larmann J, Herrmann S, Steppmann J, Schober O, Hildebrand R, Schulz R, Heus G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J and Levkau B. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006; 114: 1403-1409

70) Herzog C, Schmitz M, Levkau B, Herrgott I, Mersmann J, Larmann J, Johanning K, Winterhalter M, Chun J, Muller FU, Eichertmeyer F, Hildebrand R and Theilmeier G. Intravenous sphingosylphosphorylcholine protects ischemic and postischemic myocardial tissue in a mouse model of myocardial ischemia/reperfusion injury. Mediators Inflamm. 2010; 2010: 425191

71) Morel S, Frias MA, Rosker C, James RW, Rohr S and Kwak BR. The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovasc Res. 2012; 93: 41-49

72) Frias MA, Lecour S, James RW and Pedretti S. High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT. 2012; 1: 92-100

73) Frias MA, Pedretti S, Hacking D, Somers S, Lacerda L, Opie LH, James RW and Lecour S. HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis. 2013; 228: 110-116

74) Shende P, Plaisance I, Morandi C, Pelleluec C, Berthonneche C, Zorzato F, Krishnan J, Lerch R, Hall MN, Ruegg MA, Pedrazzini T and Brink M. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011; 123: 1073-1082

75) Shende P, Xu L, Morandi C, Pentassuglia L, Heim P, Lebboukh S, Berthonneche C, Pedrazzini T, Kaufmann BA, Hall MN, Ruegg MA and Brink M. Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy. Cardiovasc Res. 2016; 109: 103-114

76) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B and Investigators I. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357: 2109-2122

77) Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B and Investigators I. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357: 2109-2122

78) Tanaka N, Irino Y, Shinohara M, Tsuda S, Mori T, Nagao K, Okajima F and Saku K. Correlation of high density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT. 2012; 1: 92-100

79) Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sasaki M, Mori K, Kondo K, Nakajima H, Honjo T, Irino Y, Toh R, Shinohara M and Hirata K. Administration of high density lipoprotein/sphingosine-1-phosphate levels receiving intensive statin therapy. N Engl J Med. 2011; 365: 2255-2267

80) Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sasaki M, Mori K, Kondo K, Nakajima H, Honjo T, Irino Y, Toh R, Shinohara M and Hirata K. Administration of high density lipoprotein/sphingosine-1-phosphate levels receiving intensive statin therapy. N Engl J Med. 2011; 365: 2255-2267